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Abstract
Aims: The PROMUS™ Element™ European Post-Approval Surveillance Study (PE-Prove) is a prospec-
tive, open-label, multicentre observational study designed to assess outcomes following PROMUS Element 
everolimus-eluting stent implantation in an unselected patient population.
Methods and results: A total of 1,010 patients were enrolled at 40 clinical sites in Europe, including 24.9% 
with medically treated diabetes, 50.0% with Type B2/C lesions, 6.1% with chronic total occlusion, 17.8% 
with acute myocardial infarction (MI ≤24 hours pre-procedure), and 20.1% with unstable angina. The target 
lesion was the culprit for ST-segment elevation MI in 7.3% of patients. The one-year, per patient target ves-
sel failure rate was 6.2% (60/975), 3.4% (33) being related to the PROMUS Element stent. Rates of cardiac 
death, MI, and Academic Research Consortium (ARC) definite/probable stent thrombosis were 1.7%, 3.5%, 
and 0.6%, respectively. The target vessel revascularisation rate was 3.2% (31/975), 2.1% (20) being related 
to the PROMUS Element stent.
Conclusions: In a large and relatively complex group of “real-world” patients, coronary artery revasculari-
sation with the PROMUS Element everolimus-eluting stent provides favourable results with low event rates 






























As new coronary stent designs become approved and more widely 
available for use in large, unselected populations outside of con-
trolled clinical trials, it is important to evaluate their safety and 
effectiveness in broader “real-world” application. The PROMUS 
Element™ coronary stent (Boston Scientific Corporation, 
Marlborough, MA, USA) is a thin-strut, platinum chromium alloy 
stent coated with a durable, biocompatible, inert fluorocopolymer 
and everolimus as the antiproliferative agent. In the randomised 
controlled PLATINUM trial, the PROMUS Element stent was 
shown to be non-inferior to the predicate XIENCE V/PROMUS 
stent (Boston Scientific) for the primary endpoint of one-year target 
lesion failure1. Rates of all-cause death, cardiac death, myocardial 
infarction, stent thrombosis, and revascularisation were comparable 
between the two treatment groups at three-year follow-up2.
The PROMUS™ Element™ European Post-Approval Surveil-
lance Study (PE-Prove) is an observational study designed to col-
lect data on long-term outcomes in a large and relatively complex 
group of “real-world” patients treated with the PROMUS stent. We 
report here the one-year primary endpoint clinical outcomes, eval-
uating the safety and efficacy of this stent in a large, unselected 
patient population.
Methods
This prospective, open-label, multicentre study with an all-comers 
approach was designed to enrol approximately 1,000 patients at 
40 sites in Europe.
PATIENT SELECTION, PROCEDURE, AND FOLLOW-UP
All patients who were candidates for coronary artery stenting and eli-
gible to receive a PROMUS Element stent were evaluated for enrol-
ment in this study. All enrolled patients signed a written informed 
consent form that had been approved by the independent ethics com-
mittee at each study site. Enrolment was considered complete upon 
signing the informed consent form. This study was conducted in 
accordance with the ethical principles originating in the Declaration 
of Helsinki and consistent with good clinical practice and applicable 
local regulatory requirements (ClinicalTrials.gov NCT01148329).
Follow-up assessments, including medications, NYHA/CCS 
classification, adverse events, and coronary angiograms performed 
according to standard of care at each study site, were carried out by 
clinic visit or phone call at 30 days, six months, and 12 months post 
index stent implantation, and will continue annually to five years.
STUDY ENDPOINTS
The primary endpoint of this study was the overall and PROMUS 
Element stent-related target vessel failure (TVF) rate, defined 
as cardiac death, myocardial infarction (MI) related to the target 
vessel, or target vessel reintervention (TVR), at 12 months post 
stent implantation. Secondary endpoints are detailed in the Online 
Appendix. An independent clinical events committee adjudicated 
all deaths, MI, TVR, and stent thrombosis, including the relation-
ship of the event to the study stent.
STATISTICAL METHODS
Enrolled patients who received at least one PROMUS Element stent 
in the target lesion were included in the analysis. Statistical analyses 
were performed using SAS®, Version 9 or later (SAS Institute Inc., 
Cary, NC, USA). Further details are provided in the Online Appendix.
Results
PATIENT, LESION, AND PROCEDURAL CHARACTERISTICS
Of 1,010 patients enrolled at 40 clinical sites in Europe between 
28 June 2010 and 20 April 2011, one-year clinical follow-up was 
available for 975 (96.5%) patients (Figure 1). Baseline patient and 
lesion characteristics are shown in Table 1.
Procedural characteristics are shown in Online Table 1. 
Successful deployment of the PROMUS Element stent to the tar-
get lesion without device malfunction (i.e., technical success) was 
achieved in 99.8% (1,008/1,010) of patients. Two cases of longitu-
dinal stent deformation were detected by angiography during the 
index procedure, both of which involved <5% proximal stent com-
pression. Details of these cases are provided in the Online Appendix.
ONE-YEAR CLINICAL OUTCOMES
As shown in Table 2, the overall one-year TVF rate was 6.2% and 
TVF related to the PROMUS Element stent was 3.4%. The rates of 
cardiac death, MI, and TVR related to the PROMUS Element stent 
were 0.4%, 2.1%, and 2.1%, respectively. ARC-defined definite/
probable stent thrombosis related to the PROMUS Element stent 
was reported in six patients (0.6%). In Figure 2, showing Kaplan-
Meier time-to-event analyses for overall TVF and definite/probable 
stent thrombosis at one-year follow-up, there were no stent throm-
boses reported beyond eight months post procedure. One-year 
clinical outcomes for selected high-risk patient subgroups are also 
shown in Table 2. Relative to the study population as a whole, rates 
of overall and PROMUS Element-related TVF and ARC-defined 
definite/probable stent thrombosis were only modestly higher in 









No 1-year follow-up: 35
Withdrew consent: 3
Lost to follow-up: 2
Missed 1-year visit: 30
Figure 1. PE-Prove registry enrolment and follow-up.























single lesion), whereas rates among patients with small vessels 
(≤2.5 mm) were similar to the overall study population rates.
At the time of the one-year follow-up visit, 79.6% (756/950) 
of patients were taking dual antiplatelet therapy, including 96.8% 
(920/950) on aspirin, 76.1% (723/950) on clopidogrel, 6.2% 
(59/950) on prasugrel, and 0.1% (1/950) on ticagrelor.
Table 1. Baseline patient and lesion characteristics.






Insulin-treated diabetes 8.2% (83/1,010)
Current smoker 24.6% (248/1,010)
Prior PCI 38.8% (392/1,010)
Prior CABG 8.0% (81/1,010)
History of congestive heart failure 11.6% (117/1,010)
History of multivessel disease 35.8% (362/1,010)
History of bleeding disorder 1.3% (13/1,010)
History of renal disease 9.9% (100/1,010)
Prior MI (>24 hrs before index procedure) 34.4% (347/1,010)
Prior MI (≤24 hrs before index procedure) 17.8% (180/1,010)
Current 
angina status¶
 Stable angina 40.8% (412/1,010)
 Silent ischaemia 10.8% (109/1,010)
 ACS/unstable angina 13.9% (140/1,010)
 ACS/STEMI 8.0% (81/1,010)
 ACS/NSTEMI 9.8% (99/1,010)
 Unknown 24.1% (243/1,010)
Target lesion characteristics (per lesion) 1,321 lesions % (n/N)
Culprit lesion for STEMI 7.3% (96/1,321)
De novo lesions 87.4% (1,154/1,321)
In-stent restenosis (DES) 2.5% (33/1,321)
In-stent restenosis (BMS) 3.6% (47/1,321)
Total occlusion (<3 months) 6.9% (91/1,321)
Chronic total occlusion (>3 months) 6.1% (81/1,321)
Left main stenting 3.1% (41/1,321)
Bifurcation lesion 14.3% (189/1,321)
AHA/ACC type B2/C 50.0% (659/1,317)
Pre-procedure TIMI flow 0/1 19.5% (256/1,313)
Moderate/severe calcification 21.4% (283/1,321)
Moderate/severe tortuosity 10.7% (142/1,321)
Thrombus present 7.6% (100/1,321)
Reference vessel diameter, mm 3.0±0.5 (1,264)
Lesion length, mm 19.7±12.7 (1,264)
Diameter stenosis, % 84.1±12.5 (1,316)
Intent-to-treat analysis set. Values are mean±SD (N) or % (n/N). 
Denominators may differ due to missing data. *Requiring medication. 
¶Patients may be reported in more than one angina category (for 
example, a patient with silent ischaemia who subsequently had elevated 
enzymes could be reported in both categories). BMS: bare metal stent; 
CABG: coronary artery bypass graft; DES: drug-eluting stent; MI: 
myocardial infarction; PCI: percutaneous coronary intervention; STEMI: 
ST-segment elevation MI
PREDICTORS OF TARGET VESSEL FAILURE AT ONE YEAR
Multivariate predictors of TVF within one year of stent implanta-
tion are shown in Online Figure 1. Diabetes, post-procedure dila-
tion, and prior PCI were identified as predictors of both overall TVF 
and PROMUS Element stent-related TVF. The strongest predictor 
of overall TVF was the use of thienopyridines for six months or less, 
and the strongest predictor of TVF associated with the PROMUS 
Element stent was implantation in a vein graft.
Discussion
In this large, “real-world” population, one-year rates of cardiac 
death, MI, TVR, and stent thrombosis related to the PROMUS 
Element stent were low and consistent with rates in the randomised 
controlled PLATINUM trial of this stent1. Overall, clinical event 
rates for patients with small calibre vessels (≤2.5 mm) were similar 
to the rates in the study population as a whole.
As might be expected, medically treated diabetes and single 
lesion length >28 mm were each associated with modestly increased 
rates of cardiac events. The technical success rate of 99.8% reflects 
good deliverability of this stent, which is perhaps a reflection of the 
conformability and flexibility of this stent platform.
DES IN ROUTINE PRACTICE
This study contributes to a vast and growing body of “real-world” 
data on contemporary DES outcomes. Studies of DES that have 
used broad inclusion criteria or an all-comers approach include 
0.6 %
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Figure 2. Kaplan-Meier time-to-event analyses baseline to one year. 
























the PEXIP study of the XIENCE Prime and PROMUS Element 
everolimus-eluting stents3, the Swedish Coronary Angiography 
and Angioplasty Registry (SCAAR) analysis of the PROMUS 
Element stent relative to other contemporary DES4, the XIENCE V 
USA study of the XIENCE V stent5, the PROENCY registry of the 
PROMUS everolimus-eluting stent, CYPHER sirolimus-eluting 
stent, and ENDEAVOR zotarolimus-eluting stent6, the COMPARE 
study of the PROMUS everolimus-eluting stent and the TAXUS 
Liberté stent7, and three studies of the Resolute zotarolimus-elut-
ing stent, including the RESOLUTE International Registry8, the 
Resolute All Comers trial9, and the TWENTE trial10, the latter two 
both evaluating the Resolute stent versus the XIENCE V stent.
One-year clinical event rates with the PROMUS Element stent in 
this study are well within the one-year ranges reported from these 
other all-comers DES studies. The PROMUS Element all-cause 
mortality rate was 2.7% (other studies 1.6% to 2.8%), the rate of MI 
related to the PROMUS Element was 2.1% (other studies 0.7% to 
7.9%), and the rate of TVR related to the PROMUS Element was 
2.1% (other studies 1.3% to 8.2%)3-10. The 0.6% rate of ARC-defined 
definite/probable stent thrombosis is in the lower range among the 
all-comers DES studies (other studies 0.0% to 1.6%)3-6,8-11.
STENT DEFORMATION
The occurrence of two cases of longitudinal stent deformation 
(change in axial length) out of 1,679 stents placed in this study 
highlights the low frequency of this procedural complication. These 
two cases of stent deformation, which were detected by angiog-
raphy during the index procedure, represent classic examples of 
stent deformation resulting from interaction between an ancillary 
device and a stent that were easily treated without severe adverse 
consequences.
LIMITATIONS
As a single-arm registry, this study has inherent limitations. 
Without a control group, the performance of the PROMUS Element 
stent cannot be directly compared with other contemporary DES. 
In addition, the broad inclusion criteria and observational design 
present challenges for evaluating outcomes across studies in which 
the “all-comers” design results in diverse patient and lesion char-
acteristics. Finally, clinical follow-up at one year was not available 
for 3.5% of these unselected patients, mostly due to missed visits. 
Although this represents an acceptable rate of follow-up for a post-
market, all-comers registry, given the very low rate of events at one 
year with this contemporary stent, the potential effect of these miss-
ing data should be taken into account when considering the one-
year clinical event rates.
CONCLUSIONS
In this large and relatively complex group of “real-world” patients, 
coronary artery revascularisation with the PROMUS Element 
everolimus-eluting stent resulted in low clinical event rates consist-
ent with those reported for other contemporary DES.







Small diameter vessels 
(RVD ≤2.5 mm) (N=280)
Target vessel failure 6.2% (60/975) 11.0% (26/237) 7.8% (12/154) 6.6% (18/273)
Related to PROMUS Element 3.4% (33/975) 6.3% (15/237) 5.8% (9/154) 4.0% (11/273)
Major adverse cardiac events 6.6% (64/975) 12.2% (29/237) 8.4% (13/154) 7.7% (21/273)
All death or MI 5.4% (53/975) 12.2% (29/237) 7.8% (12/154) 6.6% (18/273)
Cardiac death or MI 4.6% (45/975) 11.0% (26/237) 6.5% (10/154) 5.9% (16/273)
Related to PROMUS Element 2.3% (22/975) 5.5% (13/237) 4.5% (7/154) 2.9% (8/273)
All death 2.7% (26/975) 5.9% (14/237) 2.6% (4/154) 2.6% (7/273)
Non-cardiac death 0.9% (9/975) 1.7% (4/237) 1.3% (2/154) 1.1% (3/273)
Cardiac death 1.7% (17/975) 4.2% (10/237) 1.3% (2/154) 1.5% (4/273)
Related to PROMUS Element 0.4% (4/975) 1.7% (4/237) 0.6% (1/154) 0.4% (1/273)
Related to target vessel 0.6% (6/975) 1.7% (4/237) 0.6% (1/154) 0.7% (2/273)
MI 3.5% (34/975) 8.0% (19/237) 5.2% (8/154) 5.1% (14/273)
Related to PROMUS Element 2.1% (20/975) 4.6% (11/237) 3.9% (6/154) 2.9% (8/273)
Related to target vessel 2.7% (26/975) 5.9% (14/237) 3.9% (6/154) 3.3% (9/273)
Q-wave MI 0.3% (3/975) 1.3% (3/237) 0.0% (0/154) 0.4% (1/273)
Non-Q-wave MI 3.2% (31/975) 6.8% (16/237) 5.2% (8/154) 4.8% (13/273)
Target vessel revascularisation 3.2% (31/975) 4.6% (11/237) 4.5% (7/154) 3.3% (9/273)
Related to PROMUS Element 2.1% (20/975) 3.8% (9/237) 3.9% (6/154) 2.2% (6/273)
ARC definite/probable stent thrombosis 0.6% (6/975) 2.1% (5/237) 1.3% (2/154) 0.7% (2/273)
Related to PROMUS Element 0.6% (6/975) 2.1% (5/237) 1.3% (2/154) 0.7% (2/273)
Values are % (n/N). ARC: Academic Research Consortium; MI: myocardial infarction; RVD: reference vessel diameter. *In patients with a single treated 
lesion























Impact on daily practice
Although randomised controlled trials remain the gold standard for 
proving the safety and efficacy of new devices in clinical practice, 
the strict inclusion and exclusion criteria typically used in these tri-
als mean that the results may not be generalisable to an unselected, 
“real-world” clinical population. This large, multicentre registry 
presents valuable information on outcomes from everyday clinical 
practice with the use of the PROMUS Element stent in more than 
1,000 patients in Europe. The consistency of the results from this 
more complex clinical population with those of the randomised 
controlled trial provide reassurance to the treating physician of 
good clinical outcomes with the PROMUS Element stent, regard-
less of patient comorbidities and anatomic complexity.
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PATIENT SELECTION, PROCEDURE, AND FOLLOW-UP
The following procedural data were collected: lesion characteris-
tics, total procedure time, antithrombotic and antiplatelet medica-
tions administered, and serious adverse events (SAEs), including 
serious bleeding according to GUSTO classification12. Patients with 
unsuccessful implant of a study device were followed only up to 
hospital discharge following the initial attempted index procedure. 
Enrolment at 14 centres was eventually capped at approximately 
40 patients to prevent skewing the results with overrepresentation 
from high-volume centres.
STUDY ENDPOINTS
Secondary endpoints included stent thrombosis using Academic 
Research Consortium (ARC) definitions (i.e., definite or proba-
ble), major adverse cardiac events (i.e., cardiac death, MI, TVR), 
cardiac death, MI, TVR, all deaths, and non-cardiac deaths. 
Technical success was defined as successful deployment of 
the PROMUS Element stent to the target lesion without device 
malfunction.
STATISTICAL METHODS
Patient demographics, clinical history, risk factors, pre- and post-
procedure lesion characteristics, procedure characteristics, and 
outcome variables were summarised using descriptive statistics 
for continuous variables (mean, standard deviation, number of 
observations, minimum, and maximum) and frequency tables for 
discrete variables. Kaplan-Meier plots of time-to-event variables 
were constructed with 95% confidence intervals. Cox models were 
performed to identify risk predictors with respect to TVF rates. 
Backward selection was used to identify significant predictors with 
the threshold to stay in the model set at 0.10.
RESULTS
LONGITUDINAL STENT DEFORMATION
One case was attributed to a deep-seated guide catheter interacting 
with the proximal end of a deployed PROMUS Element stent, caus-
ing slight longitudinal compression, which was resolved with post-
dilation and additional stent deployment, without associated patient 
injury. In the second case, an LAD/diagonal branch bifurcation 
intervention, the guidewire was jailed by the proximal end of the 
stent, leading to subsequent unravelling of the guidewire into a fila-
ment proximal to the diagonal. During manoeuvres for successful 
retrieval of the wire with a snare, the proximal end of the implanted 
stent was minimally damaged. Post-dilation balloon inflations were 
performed along the entire stented segment and a stent was placed in 
the proximal LAD/left main. A small non-Q-wave MI (peak CK-MB 
43 U/L, troponin 2.4 ng/mL) occurred post procedure and the patient 
was discharged two days later. Of these two patients with longitu-
dinal stent deformation, only one experienced a small periproce-
dural enzyme leak. Neither patient has had any other clinical events 
reported up to the time this manuscript was published.
Reference
 12. The GUSTO Investigators. An international randomised trial 
comparing four thrombolytic strategies for acute myocardial infarc-
tion. The GUSTO investigators. N Engl J Med. 1993;329:673-82.
Overall predictors (n=1,010) Hazard ratio±95% CI OR 95% CI p value
Thienopyridine <6 months  3.44 1.68, 7.05 <0.001
Diabetes  2.27 1.36, 3.79 0.002
Post-procedure dilatation  2.02 1.17, 3.47 0.01
Prior PCI  1.69 1.01, 2.81 0.04
Lesion type B2/C  1.66 0.95, 2.92 0.08
 0 1 2 3 4 5 6 7
Related to PE stent (n=1,010) Hazard ratio±95% CI OR 95% CI p value
Vein graft  5.22 1.56, 17.4 0.007
Diabetes  2.29 1.14, 4.59 0.02
Post-procedure dilatation  2.04 1.00, 4.18 0.05
Prior PCI  1.92 0.96, 3.82 0.06
 0 1 2 3 4 5 6 7
 Reduced risk Increased risk
Online Figure 1. Multivariate predictors of target vessel failure within 1 year of stent implantation.























Online Table 2. Clinical investigational sites.
Principal 
investigator
Site name Site location
Rudolf Berger Allgemeines Krankenhaus AKH Vienna, Austria
Steen Carstensen Roskilde University Hospital Roskilde, Denmark
Peter Schwimmbeck Klinikum Leverkusen Leverkusen, Germany
Josepa Mauri Ferré H. Germans Trias i Pujol Barcelona, Spain
Paul Barragan Polyclinique les Fleurs Ollioules, France
Edouard Benit Virga Jesse Ziekenhuis Hasselt, Belgium
Jacques Berland Clinique Saint-Hilaire Rouen Rouen, France




Ezio Bramucci IRCCS Policlinico S. Matteo Pavia, Italy
Carlo Briguori Clinica Mediterranea Naples, Italy
Christophe Caussin Le Centre Chirurgical Marie 
Lannelongue
Le Plessis Robinson, France
Sarah Catherine Clarke Papworth Hospital Cambridge, United Kingdom
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Declan Sugrue Mater Misericordiae University 
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Dublin, Ireland
Per Thayssen University Hospital Odense, Denmark
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Foundation Trust
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Online Table 1. Procedural characteristics.
Characteristics 1,035 procedures
Emergency procedure (%)* 20.2% (209/1,035)
Pre-deployment IVUS used (%) 4.5% (60/1,321)
Predilation (%) 63.4% (838/1,321)
Stent deployment pressure (atm) 15.1±2.90
Post-dilation (%) 45.7% (604/1,321)
Post-procedure target lesion diameter 
stenosis, % 1.7±5.94 (1,321)
Average stent diameter, mm 2.9±0.46
Stents implanted per lesion, n 1.3±0.60 (1,321)
Average stent length per patient, mm 34.0±23.66 (1,010)
Average stent length per lesion, mm 26.0±16.56 (1,321)
Patients with multivessel stenting 14.3% (144/1,010)
Lesions with multiple stents 20.7% (274/1,321)
Lesions with overlapping stents 14.5% (192/1,321)
Bail-out stenting 2.9% (29/1,010)¶
Intent-to-treat analysis set. Values are mean±SD (N) or % (n/N). 
*Includes staged procedures. ¶Includes study stents and non-study 























Online Table 3. Study organisation.
Principal investigator Martyn R. Thomas, MD 
Guy’s and St. Thomas’ National Health Service Foundation Trust, London, United Kingdom
Study sponsor Boston Scientific Corporation, Inc., Marlborough, MA, USA




Clinical events committee Joseph Kannam, MD (Chair) 
Beth Israel Deaconess Medical Center
Boston, MA, USA
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